18:33 , Sep 8, 2017 |  BioCentury  |  Finance

Rig-ging an exit

Wellington Partners’ quick exit from Rigontec GmbH will not only be one of the firm’s best returns from its current fund, but could bolster its fund-raising efforts for a third life sciences fund. On Sept....
01:14 , Mar 2, 2017 |  BC Extra  |  Company News

Management tracks

Inflammatory and neurological disease company Forward Pharma A/S (NASDAQ:FWP) promoted Claus Svendsen to CEO from EVP. He replaces Peder Andersen, who will remain Forward's COO until Sept. 1. The WuXi NextCODE genomics unit of New...
21:48 , Dec 2, 2016 |  BC Week In Review  |  Company News

Chiesi, Atopix deal

Chiesi will acquire Atopix in a deal that could exceed €75 million ($80 million), including undisclosed milestones. Atopix’s OC459 , a prostaglandin D2 (PGD2) receptor subtype DP2 ( PTGDR2 ; CRTH2 ; GPR44 ; DP2;...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Timapiprant: Completed Phase III enrollment

Eleventa and Oxagen announced the completion of enrollment of 212 patients in a double-blind, placebo-controlled, Russian Phase III trial evaluating 50 mg oral timapiprant once daily for 12 weeks. Atopix has exclusive rights from Oxagen...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Financial News

Atopix Therapeutics financial update

Atopix Therapeutics Ltd. , Abingdon, U.K.   Business: Dermatology, Inflammation   Date announced: 2015-06-17   Note: Atopix raised an undisclosed amount in an extension of a series A round. New investor Silicon Valley Bank participated...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Company News

Atopix Therapeutics board of directors update

Atopix Therapeutics Ltd. , London, U.K.   Business: Dermatology   Appointed: Deborah Harland, partner at SR One, the VC arm of GlaxoSmithKline plc  ...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Financial News

Atopix Therapeutics financial update

Atopix Therapeutics Ltd. , London, U.K.   Business: Dermatology   Date announced: 2014-10-07   Note: Atopix raised an undisclosed amount in an extension of a series A round. New investor SR One participated in the...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Clinical News

OC459: Phase IIb data

A double-blind, international Phase IIb trial in 482 patients with mild to moderate persistent asthma showed that 25 mg once-daily oral OC459 met the primary endpoint of significantly increasing mean FEV1 from baseline to week...
01:58 , Mar 4, 2014 |  BC Extra  |  Clinical News

Atopix reports mixed Phase II asthma data

One dose of OC459 from Atopix Therapeutics Ltd. (London, U.K.) met the primary endpoint while two other doses missed in a Phase IIb trial to treat mild to moderate persistent asthma. In the trial, 25...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

OC459: Phase II started

Atopix began a double-blind, placebo-controlled, European Phase II trial to evaluate once-daily oral OC459 for 6 months. The trial is funded by an £1.7 million ($2.8 million) grant from the U.K. Biomedical Catalyst fund (see...